Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 91.70K | 94.50K | 7.50K | 7.60K | 31.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.70K | 94.50K | 7.50K | 7.60K | 31.20K |
| Cost of Revenue | 1.60K | 1.60K | 4.80K | 4.90K | 13.50K |
| Gross Profit | 90.10K | 92.90K | 2.70K | 2.70K | 17.80K |
| SG&A Expenses | 778.70K | 803.10K | 934.80K | 942.80K | 1.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -108.70K | -112.10K | -99.60K | -100.40K | -34.50K |
| Total Operating Expenses | 1.58M | 1.63M | 1.67M | 1.68M | 2.58M |
| Operating Income | -1.48M | -1.53M | -1.66M | -1.67M | -2.55M |
| Income Before Tax | -1.48M | -1.53M | -1.64M | -1.65M | -2.57M |
| Income Tax Expenses | -- | -- | -- | -- | -33.90K |
| Earnings from Continuing Operations | -1.48M | -1.53M | -1.64M | -1.65M | -2.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.48M | -1.53M | -1.64M | -1.65M | -2.53M |
| EBIT | -1.48M | -1.53M | -1.66M | -1.67M | -2.55M |
| EBITDA | -1.44M | -1.46M | -1.54M | -1.55M | -2.49M |
| EPS Basic | -0.04 | -0.04 | -0.04 | -0.04 | -0.09 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.06 |
| EPS Diluted | -0.04 | -0.04 | -0.04 | -0.04 | -0.09 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.06 |
| Average Basic Shares Outstanding | 41.43M | 41.43M | 41.43M | 41.43M | 28.85M |
| Average Diluted Shares Outstanding | 41.43M | 41.43M | 41.43M | 41.43M | 28.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |